Engineered immune cells take on lupus and scleroderma in early trial
NCT ID NCT06375993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose and see if it can control disease activity, though long-term medication may still be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adicet Clinical Trials
Redwood City, California, 94065, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?